Amendments to the Specification

1. (currently amended) A compound represented by a formula ~~I~~ below or a pharmaceutically acceptable salt ~~or a prodrug derivative~~ thereof:



wherein;

R and R' are independently C_1-C_5 alkyl, ~~C_1-C_5 fluoroalkyl,~~ or together R and R' form ~~a substituted or unsubstituted, saturated or unsaturated~~ carbocyclic ring having from 3 to 8 carbon atoms;

~~R_{PH} is hydrogen or methyl;~~

R1 and R2 are independently ~~selected from the group consisting of~~ hydrogen or ~~,~~ ~~halo,~~ C_1-C_5 alkyl~~, C_1-C_5 fluoroalkyl, O C_1-C_5 alkyl, S C_1-C_5 alkyl, O C_1-C_5 fluoroalkyl, CN, NO_2, acetyl, S C_1-C_5 fluoroalkyl, C_2-C_5 alkenyl, C_3-C_5 cycloalkyl, and C_3-C_5 cycloalkenyl;~~

L_1 is a divalent linking group selected from: a bond,  ,  ,  ,  ,  , and  ;



and L_2 is a divalent linking group selected from: a bond and

~~and L_3 are divalent linking groups independently selected from the group consisting of~~





where m is 0, 1 or 2, ~~X_1 is oxygen or sulfur,~~ and each R40 is independently hydrogen, C_1-C_5 alkyl, or C_1-C_5 fluoroalkyl;

R_{BOH} is

3-methyl-3-hydroxypentyl,

3-methyl-3-hydroxypentenyl,

3-methyl-3-hydroxypentynyl,

3-ethyl-3-hydroxypentyl,

3-ethyl-3-hydroxypentenyl,

3-ethyl-3-hydroxypentynyl,

3-ethyl-3-hydroxy-4-methylpentyl,
3-ethyl-3-hydroxy-4-methylpentenyl,
3-ethyl-3-hydroxy-4-methylpentynyl,
3-propyl-3-hydroxypentyl,
3-propyl-3-hydroxypentenyl,
3-propyl-3-hydroxypentynyl,
1-hydroxy-2-methyl-1-(methylethyl)propyl,
~~1-hydroxycyclopentenyl,~~
~~1-hydroxycyclohexenyl,~~
~~1-hydroxycycloheptenyl,~~
~~1-hydroxycyclooctenyl,~~
1-hydroxycyclopropyl,
1-hydroxycyclobutyl,
1-hydroxycyclopentyl, or
1-hydroxycyclohexyl;~~,~~
~~1-hydroxycycloheptyl, or~~
~~1-hydroxycyclooctyl;~~

provided, however, that when

R_{BOH} is

3-methyl-3-hydroxypentyl,
3-methyl-3-hydroxypentenyl,
3-methyl-3-hydroxypentynyl,
3-ethyl-3-hydroxypentyl,
3-ethyl-3-hydroxypentenyl,
3-ethyl-3-hydroxypentynyl,
3-ethyl-3-hydroxy-4-methylpentyl,
3-ethyl-3-hydroxy-4-methylpentenyl,
3-ethyl-3-hydroxy-4-methylpentynyl,
3-propyl-3-hydroxypentyl,
3-propyl-3-hydroxypentenyl,
3-propyl-3-hydroxypentynyl, or
1-hydroxy-2-methyl-1-(methylethyl)propyl;

then L_1 and L_2 combine as a bond; and

R_C is

~~CO_2H,~~

~~CO_2Me,~~

~~CO_2Et,~~

~~$C(O)CH_2S(O)Me$.~~

~~$C(O)CH_2S(O)Et$.~~

~~$C(O)CH_2S(O)_2Me$,~~

~~$C(O)CH_2S(O)_2Et$,~~

~~$C(O)CH_2CH_2S(O)Me$.~~

~~$C(O)CH_2CH_2S(O)Et$,~~

~~$C(O)CH_2CH_2S(O)_2Me$,~~

~~$C(O)CH_2CH_2S(O)_2Et$,~~

~~$C(O)CHMeCH_2CO_2H$~~

~~$C(O)C(O)OH$,~~

~~$C(O)C(O)NH_2$;~~

~~$C(O)C(O)NHMe$,~~

~~$C(O)C(O)NMe_2$;~~

~~$C(O)NH_2$. $C(O)NMe_2$;~~

~~$C(O)NHS(O)Me$,~~

~~$C(O)NHSO_2Me$,~~

~~C(O) NH 5 tetrazolyl,~~

~~C(O)NMe 5 tetrazolyl,~~

~~C(O)NHS(O)Me,~~

~~C(O)NHS(O)Et.~~

~~$C(O)NHSO_2Me$,~~

~~$C(O)NHSO_2Et$,~~

~~-C(O)NHS(O)iPr,~~

~~-C(O)NHSO$_2$iPr,~~

~~-C(O)NHS(O)nPr.~~

~~-C(O)NHSO$_2$nPr,~~

~~-C(O)NHCH$_2$S(O)Me,~~

~~-C(O)NHCH$_2$S(O)Et,~~

~~-C(O)NHCH$_2$SO$_2$Me,~~

~~-C(O)NHCH$_2$SO$_2$Et,~~

~~-C(O)NHCH$_2$CH$_2$S(O)Me,~~

~~-C(O)NHCH$_2$CH$_2$S(O)Et,~~

~~-C(O)NHCH$_2$CH$_2$SO$_2$Me,~~

~~-C(O)NHCH$_2$CH$_2$SO$_2$Et,~~

~~-C(O)NH$_2$,~~

~~-C(O)NMe$_2$,~~

-C(O)NH-CH$_2$-C(O)OH,

-C(O)NH-CH(Me)-C(O)OH,

~~-C(O)NH-CH(F)-C(O)OH,~~

~~-C(O)NH-CH(CF$_3$)-C(O)OH,~~

~~-C(O)NH-CH(OH)-C(O)OH,~~

~~-C(O)NH-CH(cyclopropyl)-C(O)OH.~~

-C(O)NH-C(Me)$_2$-C(O)OH,

~~-C(O)NH-C(Me)$_2$-C(O)OH.~~

~~-C(O)NH-CF(Me)-C(O)OH,~~

~~-C(O)NH-C(Me)(CF$_3$)-C(O)OH.~~

~~-C(O)NH-C(Me)(OH)-C(O)OH.~~

~~-C(O)NH-C(Me)(cyclopropyl-C(O)OH,~~

-C(O)NMe-CH$_2$-C(O)OH,

-C(O)NMe-CH(Me)-C(O)OH,

~~-C(O)NMe-CH(F)-C(O)OH.~~

~~-C(O)NMe-CH(CF$_3$)-C(O)OH.~~

~~-C(O)NMe-CH(OH)-C(O)OH,~~

~~-C(O)NMe-CH(cyclopropyl)-C(O)OH,~~

-C(O)NMe-C(Me)$_2$-C(O)OH, or

~~-C(O)NMe-CF(Me)-C(O)OH,~~

~~-C(O)NMe-C(Me)(CF$_3$)-C(O)OH.~~

~~-C(O)NMe-C(Me)(OH)-C(O)OH,~~

~~-C(O)NMe-C(Me)(cyclopropyl)-C(O)OH,~~

~~-CH$_2$-CO$_2$H,~~

~~-CH$_2$-5-tetrazolyl.~~

~~-CH$_2$-CO$_2$Me.~~

~~-CH$_2$CO$_2$Et,~~

~~-CH$_2$NHS(O)Me,~~

~~-CH$_2$NHS(O)Et,~~

~~-CH$_2$NHSO$_2$Me,~~

~~-CH$_2$NHSO$_2$Et,~~

~~-CH$_2$NHS(O)iPr.~~

~~-CH$_2$NHSO$_2$iPr,~~

~~-CH$_2$NHS(O)nPr.~~

~~-CH$_2$NHSO$_2$nPr,~~

~~-CH$_2$NHCH$_2$CH$_2$SO$_2$CH$_3$,~~

~~-CH$_2$NH(CH$_2$CO$_2$H),~~

~~-CH$_2$N(C(O)Me)(CH$_2$CO$_2$H),~~

~~-CH$_2$-N-pyrrolidin-2-one,~~

~~-CH$_2$-(1-methylpyrrolidin-2-one-3-yl).~~

~~-CH$_2$S(O)Me,~~

~~-CH$_2$S(O)Et,~~

~~-CH$_2$S(O)$_2$Me,~~

~~-CH$_2$S(O)$_2$Et,~~

~~-CH$_2$S(O)iPr,~~

~~-CH$_2$S(O)$_2$iPr,~~

~~-CH$_2$S(O)nPr,~~

~~-CH$_2$S(O)$_2$nPr,~~

~~CH_2CO_2H, $CH_2C(O)NH_2$,~~

~~$CH_2C(O)NMe_2$,~~

~~$CH_2C(O)NHMe$,~~

~~$CH_2C(O)$-N-pyrrolidine,~~

~~$CH_2S(O)_2Me$,~~

~~$CH_2S(O)Me$.~~

~~$CH(OH)CO_2H$.~~

~~$CH(OH)C(O)NH_2$,~~

~~$CH(OH)C(O)NHMe$,~~

~~$CH(OH)C(O)NMe_2$,~~

~~$CH(OH)C(O)NEt_2$,~~

~~$CH_2CH_2CO_2H$.~~

~~$CH_2CH_2CO_2Me$,~~

~~$CH_2CH_2CO_2Et$,~~

~~$CH_2CH_2C(O)NH_2$.~~

~~$CH_2CH_2C(O)NHMe$.~~

~~$CH_2CH_2C(O)NMe_2$,~~

~~CH_2CH_2-5-tetrazolyl,~~

~~$CH_2CH_2S(O)_2Me$,~~

~~$CH_2CH_2S(O)Me$.~~

~~$CH_2CH_2S(O)_2Et$,~~

~~$CH_2CH_2S(O)Et$,~~

~~$CH_2CH_2S(O)iPr$,~~

~~$CH_2CH_2S(O)_2iPr$,~~

~~$CH_2CH_2S(O)nPr$.~~

~~$CH_2CH_2S(O)_2nPr$,~~

~~$CH_2CH_2S(O)NH_2$.~~

~~$CH_2CH_2S(O)NHMe$.~~

~~$CH_2CH_2S(O)NMe_2$,~~

~~$-CH_2CH_2S(O)_2NH_2$,~~

~~$-CH_2CH_2S(O)_2NHMe$,~~

~~$-CH_2CH_2S(O)_2NMe_2$.~~

~~$-CH_2CH_2CH_2S(O)Me$,~~

~~$-CH_2CH_2CH_2S(O)Et$,~~

~~$-CH_2CH_2CH_2S(O)_2Me$,~~

~~$-CH_2CH_2CH_2S(O)_2Et$,~~

~~$-CH(Me)CH_2C(O)OH$.~~

~~$-C(Me)_2CH_2C(O)OH$,~~

~~$-SO_3H$,~~

-5-tetrazolyl,













or



~~1,3,4-oxadiazolin-2-one-5-yl,~~

~~imidazolidine-2,4-dione-5-yl,~~

~~1,3-thiazolidine-2,4-dione-5-methylidene,~~

~~isoxazol-3-ol-yl, or~~

~~1,3,4-oxadiazolin-2-thione-5-yl.~~

2. (canceled)

3. (currently amended) A compound represented by formula (II) or a pharmaceutically acceptable salt ~~or an ester prodrug derivative~~ thereof:



(II)

wherein;

R and R' are independently methyl or ethyl;

R1 and R2 are independently ~~hydrogen, halo, CF_3,~~ methyl~~,~~ or ethyl~~;, or cyclopropyl;~~

L_1 is a divalent linking group selected from: a bond a bond,  ,  ,  ,  ,  , and  ;



and L_2 is a divalent linking group selected from: a bond and

~~and L_2 are independently divalent linking groups independently selected from~~

~~a bond ,~~



where m is 0 or 1;

R_{BOH} is selected from

~~1-hydroxycyclopentenyl,~~

~~1-hydroxycyclohexenyl,~~

1-hydroxycyclopentyl, or

1-hydroxycyclohexyl, and

R_C is a group selected from

~~CO_2H,~~

~~CO_2Me,~~

~~CO_2Et,~~

~~$C(O)NH_2$,~~

~~$C(O)NMe_2$,~~

-C(O)NH-CH_2-C(O)OH,

-C(O)NH-CH(Me)-C(O)OH,

~~-C(O)NH-CH(F)-C(O)OH,~~

~~-C(O)NH-CH(CF_3)-C(O)OH,~~

~~-C(O)NH-CH(OH)-C(O)OH,~~

~~-C(O)NH-CH(cyclopropyl)-C(O)OH,~~

-C(O)NH-$C(Me)_2$-C(O)OH,

~~-C(O)NH-$C(Me)_2$-C(O)OH,~~

~~-C(O)NH-CF(Me)-C(O)OH,~~

~~-C(O)NH-C(Me)(CF_3)-C(O)OH,~~

~~-C(O)NH-C(Me)(OH)-C(O)OH,~~

~~-C(O)NH-C(Me)(cyclopropyl-C(O)OH,~~

-C(O)NMe-CH_2-C(O)OH,

-C(O)NMe-CH(Me)-C(O)OH, or

~~-C(O)NMe-CH(F)-C(O)OH,~~

~~-C(O)NMe-CH(CF_3)-C(O)OH,~~

~~-C(O)NMe-CH(OH)-C(O)OH,~~

~~-C(O)NMe-CH(cyclopropyl)-C(O)OH,~~

-C(O)NMe-$C(Me)_2$-C(O)OH,

~~-C(O)NMe-CF(Me)-C(O)OH,~~

~~-C(O)NMe-C(Me)(CF_3)-C(O)OH,~~

~~-C(O)NMe-C(Me)(OH)-C(O)OH,~~

~~-C(O)NMe-5-tetrazolyl,~~

~~-C(O)NMe-C(Me)(cyclopropyl)-C(O)OH, or~~

~~-C(O)-NH-5-tetrazolyl.~~

4. (currently amended) A compound represented by formula (III) or a pharmaceutically acceptable salt ~~or an ester prodrug derivative~~ thereof:



(III)

wherein;

R and R' are independently methyl or ethyl;

R1 and R2 are independently ~~hydrogen, halo, CF_3,~~ methyl~~,~~ or ethyl~~;~~ ~~or cyclopropyl;~~

R_{BOH} is selected from

3-methyl-3-hydroxypentyl,

~~5~~3-methyl-3-hydroxypentenyl,

3-methyl-3-hydroxypentynyl,

3-ethyl-3-hydroxypentyl,

3-ethyl-3-hydroxypentenyl,

3-ethyl-3-hydroxypentynyl,

3-propyl-3-hydroxypentyl,

3-propyl-3-hydroxypentenyl,

3-propyl-3-hydroxypentynyl,

3-ethyl-3-hydroxy-4-methylpentyl,

3-ethyl-3-hydroxy-4-methylpentenyl,

3-ethyl-3-hydroxy-4-methylpentynyl, or

1-hydroxy-2-methyl-1-(methylethyl)propyl;

and

R_C is a group selected from

~~$-CO_2H$,~~

~~$-CO_2Me$,~~

~~$-CO_2Et$.~~

~~$-C(O)NH_2$.~~

~~$-C(O)NMe_2$.~~

$-C(O)NH-CH_2-C(O)OH$,

-C(O)NH-CH(Me)-C(O)OH,

~~-C(O)NH-CH(F)-C(O)OH.~~

~~$-C(O)NH-CH(CF_3)-C(O)OH$.~~

~~-C(O)NH-CH(OH)-C(O)OH.~~

~~-C(O)NH-CH(cyclopropyl)-C(O)OH.~~

$-C(O)NH-C(Me)_2-C(O)OH$,

$-C(O)NH-C(Me)_2-C(O)OH$,

~~-C(O)NH-CF(Me)-C(O)OH.~~

~~-C(O)NH-C(Me)(CF_3)-C(O)OH,~~

~~-C(O)NH-C(Me)(OH)-C(O)OH,~~

~~-C(O)NH-C(Me)(cyclopropyl-C(O)OH,~~

-C(O)NMe-CH_2-C(O)OH,

-C(O)NMe-CH(Me)-C(O)OH,

~~-C(O)NMe-CH(F)-C(O)OH,~~

~~-C(O)NMe-CH(CF_3)-C(O)OH,~~

~~-C(O)NMe-CH(OH)-C(O)OH,~~

~~-C(O)NMe-CH(cyclopropyl)-C(O)OH,~~

-C(O)NMe-C(Me)$_2$-C(O)OH, and

~~-C(O)NMe-CF(Me)-C(O)OH,~~

~~-C(O)NMe-C(Me)(CF_3)-C(O)OH,~~

~~-C(O)NMe-C(Me)(OH)-C(O)OH,~~

~~-C(O)NMe-5-tetrazolyl,~~

~~-C(O)NMe-C(Me)(cyclopropyl)-C(O)OH, or~~

-C(O)-NH-5-tetrazolyl.

5. (currently amended) ~~The~~A compound represented by formula (AA-1) to (AA-33) or a pharmaceutically acceptable salt ~~or prodrug derivative~~ thereof:

AA-1)



AA-2)



,

AA-3)



,

AA-4)



,

AA-5)



,

AA-6)



,

AA-7)



,

AA-8)



,

AA-9)



,

AA-10)



AA-11)



AA-12)



AA-13)



AA-14)



,

AA-15)



,

AA-16)



,

AA-17)



,

AA-18)



,

AA-19)



,

AA-20)



,

AA-21)



,

AA-22)



AA-23)



AA-24)



AA-25)



AA-26)



AA-27)



AA-28)



AA-29)



AA-30)



AA-31)



AA-32)



or

AA-33)



6. (currently amended) ~~The~~A compound represented by formula (BB-1) to (BB-33) or a pharmaceutically acceptable salt ~~or prodrug derivative~~ thereof:

BB-1)



BB-2)



BB-3)



BB-4)



BB-5)



,

BB-6)



,

BB-7)



,

BB-8)



,

BB-9)



,

BB-10)



,

BB-11)



,

BB-12)



,

BB-13)



,

BB-14)



,

BB-15)



,

BB-16)



,

BB-17)



,

BB-18)



,

BB-19)



,

BB-20)



,

BB-21)



BB-22)



BB-23)



BB-24)



BB-25)



,

BB-26)



,

BB-27)



,

BB-28)



,

BB-29)



,

BB-30)



,

BB-31)



,

BB-32)



, or

BB-33)



7. (currently amended) ~~The~~A compound represented by formula (CC-1) to (CC-44) or a pharmaceutically acceptable salt ~~or prodrug derivative~~ thereof:

CC-1)



,

CC-2)



,

CC-3)



,

CC-4)



,

CC-5)



,

CC-6)



,

CC-7)



,

CC-8)



CC-9)



CC-10)



CC-11)



CC-12)



,

CC-13)



;

CC-14)



,

CC-15)



,

CC-16)



CC-17)



CC-18)



CC-19)



CC-20)



CC-21)



CC-22)



CC-23)



CC-24)



CC-25)



CC-26)



CC-27)



CC-28)



,

CC-29)



,

CC-30)



,

CC-31)



,

CC-32)



,

CC-33)



,

CC-34)



,

CC-35)



,

CC-36)



CC-37)



CC-38)



CC-39)



CC-40)



,

CC-41)



,

CC-42)



,

CC-43)



, or

CC-44)



8. (Currently Amended) The compound according to claim 1 represented by the formula:



;

or a pharmaceutically acceptable salt ~~or prodrug derivative~~ thereof.

9. (Currently Amended) ~~The~~A compound ~~according to claim 1~~ represented by the formula:



;

or a pharmaceutically acceptable salt ~~or prodrug derivative~~ thereof.

10. (currently amended) The prodrug derivative of the A compound according to~~of~~ claim 1 wherein ~~the~~ a carboxylic acid group of R_C is esterified to~~prodrug is~~ a methyl ester; ethyl ester; N,N-diethylglycolamido ester; or morpholinylethyl ester group.

11. (previously presented) The salt derivative of the compound of claim 1 wherein the salt is sodium or potassium.

12. (withdrawn) A pharmaceutical formulation comprising the compound of claim 1 together with a pharmaceutically acceptable carrier or diluent.

13-16. (canceled)

17. (withdrawn) A method of treating a mammal to prevent or alleviate the pathological effects of Acne, Actinic keratosis, Alopecia , Alzheimer's disease, Bone maintenance in zero gravity, Bone fracture healing, Breast cancer, Chemoprovention of Cancer, Crohn's disease, Colon cancer, Type I diabetes, Host-graft rejection, Hypercalcemia , Type II diabetes, Leukemia, Multiple sclerosis, Myelodysplastic syndrome, Insufficient sebum secretion, Osteomalacia, Osteoporosis, Insufficient dermal firmness, Insufficient dermal hydration, Psoriatic arthritis, Prostate cancer, Psoriasis, Renal osteodystrophy, Rheumatoid arthritis, Scleroderma, Skin cancer, Systemic lupus erythematosus, Skin cell damage from, Mustard vesicants, Ulcerative colitis, Vitiligo, or Wrinkles; wherein the method comprises administering a pharmaceutically effective amount of at least one compound of claim 1.

18. (withdrawn) The method of claim 17 for the treatment of psoriasis.

19. (withdrawn) The method of claim 17 for the treatment of osteoporosis.

20-21. (canceled)

22. (withdrawn) A method of treating or preventing disease states mediated by the Vitamin D receptor, wherein a mammal in need thereof is administered a pharmaceutically effective amount of the compound of Claim 1.

23-28. (canceled)